Invasive pneumococcal infections in Vellore, India: clinical characteristics and distribution of serotypes

BACKGROUND: Streptococcus pneumoniae infection is a serious problem worldwide and the case fatality rate remains high. The aim of this study was to analyze the distribution of pneumococcal serotypes causing invasive pneumococcal disease (IPD), to survey the potential coverage of present and future vaccines, and to investigate differences between serotypes and groups of serotypes with regard to manifestation, case fatality rate, age, and other risk factors. METHODS: Isolates from 244 consecutive patients with IPD were collected at the Christian Medical College, Vellore, India between January 2007 and June 2011, and clinical data were obtained retrospectively. Clinical characteristics were analyzed both for individual serotypes and for those grouped as “invasive”, “pediatric”, or “vaccine” serotypes. RESULTS: The serotype coverage for the pneumococcal conjugated vaccines (PCV) PCV7, PCV10, PCV13, PCV15, and pneumococcal polysaccharide vaccine (PPV) PPV23 was 29%, 53%, 64%, 66%, and 73%, respectively. The proportion of IPD caused by vaccine types was lower than pre-vaccination studies from other parts of the world. In adults, serotype 1 was mainly isolated from previously healthy patients without risk factors for IPD. This serotype caused more pneumonia and less meningitis than other serotypes, as was also noted for the “invasive” serotypes (1, 5, and 7 F). CONCLUSIONS: The most common pneumococcal serotypes in this study behaved in similar ways to those in countries where the PCV has been introduced. Also, the most common serotypes in this study are included in the new PCVs. Therefore, a national program of childhood immunization with PCV10/13 in India is likely to be successful

Immunomodulatory effects of human beta-defensin 2 in treating asthma and COPD

University of Technology Sydney. Faculty of Science.Background: Asthma and chronic obstructive pulmonary disease (COPD) are debilitating diseases and effective therapies are a priority. Human beta-defensin 2 (hBD2) is an antimicrobial peptide with potential for treating asthma and COPD. Methods: The effects of hBD2 in allergic airway disease (AAD), severe steroid-resistant (SSRAAD), and experimental COPD murine models were assessed. In AAD, faecal microbial transfer (FMT) and flow cytometry were used to assess the role of faecal microbiome and immunomodulation in hBD2-mediated effects. Results: Intranasal hBD2 reduced airway inflammation, but partially suppressed airway hyperresponsiveness (AHR), while oral hBD2 had no effects on airway inflammation and alleviated AHR in SSRAAD. In AAD, oral hBD2 reduced AAD features. FMT from hBD2-donors did not transfer the protective effects of hBD2 in AAD. hBD2 reversed AAD-induced granulocyte depletion in the colon and reduced AAD-induced granulocytes in the lungs to suppress AAD. Intranasal hBD2 did not suppress CS-induced acute airway inflammation. High-dose oral hBD2 reduced CS-induced acute airway inflammation, however failed to suppress disease features in CS-induced experimental COPD. Conclusion: Intranasal and oral hBD2 partially alleviated SSRAAD. Oral hBD2 alleviates AAD, which is associated with the immunomodulation of colon and lung immune cells. Oral hBD2 is not effective in experimental COPD

Climate change and Indian forests

An assessment of the impact of projected climate change on forest ecosystems in India based on climate projections of the Regional Climate Model of the Hadley Centre (HadRM3) and the global dynamic vegetation model IBIS for A1B scenario is conducted for short-term (2021-2050) and long-term (2071-2100) periods. Based on the dynamic global vegetation modelling, vulnerable forested regions of India have been identified to assist in planning adaptation interventions. The assessment of climate impacts showed that at the national level, about 45% of the forested grids is projected to undergo change. Vulnerability assessment showed that such vulnerable forested grids are spread across India. However, their concentration is higher in the upper Himalayan stretches, parts of Central India, northern Western Ghats and the Eastern Ghats. In contrast, the northeastern forests, southern Western Ghats and the forested regions of eastern India are estimated to be the least vulnerable. Low tree density, low biodiversity status as well as higher levels of fragmentation, in addition to climate change, contribute to the vulnerability of these forests. The mountainous forests (sub-alpine and alpine forest, the Himalayan dry temperate forest and the Himalayan moist temperate forest) are susceptible to the adverse effects of climate change. This is because climate change is predicted to be larger for regions that have greater elevations

Photocatalytic degradation of metronidazole and methylene blue by PVA-assisted Bi2WO6–CdS nanocomposite film under visible light irradiation

Abstract The enhanced photocatalytic performance of nanocomposite is synthesized via the hydrothermal method and characterized using X-ray diffraction (XRD), X-ray photoelectron spectroscopy (XPS), field emission scanning electron microscopy (FESEM), Fourier transform infrared spectroscopy (FT-IR), UV–visible diffuse reflectance spectroscopy (UV–Vis DRS) and photoluminescence spectroscopy (PL). Under visible light irradiation, PVA assisted Bi2WO6–CdS nanocomposite film displayed enhanced photocatalytic efficiency and inhibition of photocorrosion as compared with pure CdS, pure Bi2WO6 and Bi2WO6–CdS composite. The PVA assisted Bi2WO6–CdS composite film catalyst showed stable catalytic performance until seven successive runs with 92% of methylene blue(MB) degradation, and easy to recover after degradation of organic pollutant. PVA assisted Bi2WO6–CdS nanocomposite film has optimal band edge position for superior photocatalytic degradation. Furthermore, the trapping experiment was carried out using different scavenger for active species. Among the active species, OH· are the most responsive species which play a vital role in the degradation of metronidazole and MB.</jats:p

The Role of Cytokines in Interactions of Mesenchymal Stem Cells and Breast Cancer Cells

Mesenchymal stem cells, because of their high proliferation, differentiation, regenerative capacity, and ease of availability, have been a popular choice in cytotherapy. Mesenchymal Stem Cells (MSCs) have a natural tendency to home in a tumor microenvironment and act against it, owing to the similarity of the latter to an injured tissue environment. Several studies have confirmed the recruitment of MSCs by tumor through various cytokine signaling that brings about phenotypic changes to cancer cells, thereby promoting migration, invasion, and adhesion of cancer cells. The contrasting results on MSCs as a tool for cancer cytotherapy may be due to the complex cell to cell interaction in the tumor microenvironment, which involves various cell types such as cancer cells, immune cells, endothelial cells, and cancer stem cells. Cell to cell communication can be simple or complex and it is transmitted through various cytokines among multiple cell phenotypes, mechano-elasticity of the extra- cellular matrix surrounding the cancer cells, and hypoxic environments. In this article, the role of the extra-cellular matrix proteins and soluble mediators that act as communicators between mesenchymal stem cells and cancer cells has been reviewed specifically for breast cancer, as they are the leading members of cancer malignancies. The comprehensive information may be beneficial in finding a new combinatorial cytotherapeutic strategy using MSCs by exploiting the cross-talk between mesenchymal stem cells and cancer cells for treating breast cancer. </jats:sec